- Investopedia•1 hour ago
Breakthrough designation will help faster review of Rituxan for treating rare disease Pemphigus Vulgaris
- Investopedia•2 hours ago
Bavencio, the first and only approved drug for MCC treatment, is under study for multiple other cancers.
- Business Wire•7 hours ago
Genentech, a member of the Roche Group , today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation status to Rituxan® for pemphigus vulgaris, a rare, serious and life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.2 FDA Breakthrough Therapy Designation is intended to expedite the development and review ...
RHHBY : Summary for ROCHE HLDG LTD SPONS - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||31.49 - 31.89|
|52 Week Range||25.25 - 33.77|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||22.98|
|Dividend & Yield||1.02 (3.23%)|
|1y Target Est||N/A|